Sachin Mehta, MD

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$92,633.13	30.2%	82	2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$73,566.17	24.0%	95	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$47,859.03	15.6%	49	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$37,400.02	12.2%	38	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$28,729.47	9.4%	46	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$25,952.95	8.5%	42	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$118.07	0.0%	5	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$88.95	0.0%	4	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$86.41	0.0%	4	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$79.61	0.0%	4	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$71.90	0.0%	3	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$38.31	0.0%	2	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$36.77	0.0%	2	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$30.59	0.0%	1	2025
Corium, LLC	Unresolved — no canonical attribution shown	$24.80	0.0%	1	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$23.59	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$214,642.00	85
Honoraria	$42,762.50	15
Travel and Lodging	$27,152.00	90
Consulting Fee	$11,966.00	4
Food and Beverage	$10,217.27	185

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$88,163.78	79	2025
Source payment records 2025-02-05 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-02-05 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-02-10 · E.R. Squibb & Sons, L.L.C. · $6.05 · Open Payments source 2025-02-26 · E.R. Squibb & Sons, L.L.C. · $113.93 · Open Payments source 2025-02-26 · E.R. Squibb & Sons, L.L.C. · $565.92 · Open Payments source 2025-03-04 · E.R. Squibb & Sons, L.L.C. · $120.00 · Open Payments source 2025-03-06 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-03-18 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-04-02 · E.R. Squibb & Sons, L.L.C. · $141.12 · Open Payments source 2025-04-08 · E.R. Squibb & Sons, L.L.C. · $135.00 · Open Payments source 2025-04-10 · E.R. Squibb & Sons, L.L.C. · $118.30 · Open Payments source 2025-04-23 · E.R. Squibb & Sons, L.L.C. · $102.57 · Open Payments source 2025-04-25 · E.R. Squibb & Sons, L.L.C. · $190.00 · Open Payments source 2025-04-25 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-04-29 · E.R. Squibb & Sons, L.L.C. · $2.89 · Open Payments source 2025-04-29 · E.R. Squibb & Sons, L.L.C. · $125.00 · Open Payments source 2025-05-01 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-05-05 · E.R. Squibb & Sons, L.L.C. · $198.05 · Open Payments source 2025-05-05 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-05-06 · E.R. Squibb & Sons, L.L.C. · $55.00 · Open Payments source 2025-05-06 · E.R. Squibb & Sons, L.L.C. · $634.71 · Open Payments source 2025-05-08 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-05-16 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-05-20 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-05-21 · E.R. Squibb & Sons, L.L.C. · $199.40 · Open Payments source 2025-05-22 · E.R. Squibb & Sons, L.L.C. · $3,323.00 · Open Payments source 2025-05-27 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-06-02 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-06-11 · E.R. Squibb & Sons, L.L.C. · $67.50 · Open Payments source 2025-06-12 · E.R. Squibb & Sons, L.L.C. · $814.83 · Open Payments source 2025-06-12 · E.R. Squibb & Sons, L.L.C. · $133.76 · Open Payments source 2025-06-13 · E.R. Squibb & Sons, L.L.C. · $5,538.00 · Open Payments source 2025-06-16 · E.R. Squibb & Sons, L.L.C. · $5.68 · Open Payments source 2025-06-24 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-06-24 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-06-25 · E.R. Squibb & Sons, L.L.C. · $3,323.00 · Open Payments source 2025-06-26 · E.R. Squibb & Sons, L.L.C. · $5.10 · Open Payments source 2025-06-26 · E.R. Squibb & Sons, L.L.C. · $10.22 · Open Payments source 2025-07-01 · E.R. Squibb & Sons, L.L.C. · $3,876.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $130.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $395.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-08-14 · E.R. Squibb & Sons, L.L.C. · $2,215.00 · Open Payments source 2025-09-11 · E.R. Squibb & Sons, L.L.C. · $4.66 · Open Payments source 2025-09-11 · E.R. Squibb & Sons, L.L.C. · $95.03 · Open Payments source 2025-09-12 · E.R. Squibb & Sons, L.L.C. · $695.29 · Open Payments source 2025-09-12 · E.R. Squibb & Sons, L.L.C. · $124.99 · Open Payments source 2025-09-24 · E.R. Squibb & Sons, L.L.C. · $64.26 · Open Payments source 2025-09-29 · E.R. Squibb & Sons, L.L.C. · $122.04 · Open Payments source 2025-09-29 · E.R. Squibb & Sons, L.L.C. · $1,370.31 · Open Payments source 2025-09-29 · E.R. Squibb & Sons, L.L.C. · $200.48 · Open Payments source 2025-09-30 · E.R. Squibb & Sons, L.L.C. · $119.70 · Open Payments source 2025-09-30 · E.R. Squibb & Sons, L.L.C. · $932.00 · Open Payments source 2025-10-02 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-10-02 · E.R. Squibb & Sons, L.L.C. · $3,876.00 · Open Payments source 2025-10-08 · E.R. Squibb & Sons, L.L.C. · $260.00 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $872.47 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-10-10 · E.R. Squibb & Sons, L.L.C. · $3,323.00 · Open Payments source 2025-10-14 · E.R. Squibb & Sons, L.L.C. · $4,984.00 · Open Payments source 2025-10-17 · E.R. Squibb & Sons, L.L.C. · $1,994.00 · Open Payments source 2025-10-17 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-10-22 · E.R. Squibb & Sons, L.L.C. · $2.63 · Open Payments source 2025-10-22 · E.R. Squibb & Sons, L.L.C. · $121.36 · Open Payments source 2025-11-05 · E.R. Squibb & Sons, L.L.C. · $200.00 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $300.00 · Open Payments source 2025-11-12 · E.R. Squibb & Sons, L.L.C. · $6.05 · Open Payments source 2025-11-18 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-11-19 · E.R. Squibb & Sons, L.L.C. · $86.52 · Open Payments source 2025-12-04 · E.R. Squibb & Sons, L.L.C. · $15.20 · Open Payments source 2025-12-23 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$73,566.17	95	2025
Source payment records 2025-01-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.50 · Open Payments source 2025-01-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.06 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.00 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,360.00 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $868.27 · Open Payments source 2025-02-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.89 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $250.00 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.70 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $273.62 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $320.00 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.44 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.00 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,360.00 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $920.00 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.42 · Open Payments source 2025-04-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.06 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.53 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $160.00 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.78 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $180.00 · Open Payments source 2025-05-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.84 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.94 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $127.60 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $160.00 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.00 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.61 · Open Payments source 2025-07-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.77 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,320.00 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-08-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.80 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.38 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $550.00 · Open Payments source 2025-08-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $220.00 · Open Payments source 2025-09-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $343.96 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.30 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $107.83 · Open Payments source 2025-10-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $88.20 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $86.20 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.40 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.90 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $525.00 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $677.43 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.00 · Open Payments source 2025-11-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,320.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.24 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.24 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $101.81 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.05 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.71 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.20 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.00 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $89.89 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.88 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $985.95 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $127.63 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $450.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.57 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.15 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.11 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $186.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$47,859.03	49	2025
Source payment records 2025-03-06 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-03-06 · Axsome Therapeutics, Inc. · $124.74 · Open Payments source 2025-03-06 · Axsome Therapeutics, Inc. · $187.73 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $60.36 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $125.13 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $234.83 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $460.97 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $57.26 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $470.00 · Open Payments source 2025-04-04 · Axsome Therapeutics, Inc. · $9,350.00 · Open Payments source 2025-04-08 · Axsome Therapeutics, Inc. · $211.01 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $1,650.00 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $280.00 · Open Payments source 2025-05-01 · Axsome Therapeutics, Inc. · $1,237.50 · Open Payments source 2025-05-27 · Axsome Therapeutics, Inc. · $20.44 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $1,650.00 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $601.97 · Open Payments source 2025-06-09 · Axsome Therapeutics, Inc. · $30.20 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $125.00 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $100.00 · Open Payments source 2025-06-23 · Axsome Therapeutics, Inc. · $1,100.00 · Open Payments source 2025-07-23 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-07-23 · Axsome Therapeutics, Inc. · $119.49 · Open Payments source 2025-07-23 · Axsome Therapeutics, Inc. · $100.00 · Open Payments source 2025-07-31 · Axsome Therapeutics, Inc. · $33.86 · Open Payments source 2025-07-31 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-07-31 · Axsome Therapeutics, Inc. · $121.41 · Open Payments source 2025-07-31 · Axsome Therapeutics, Inc. · $17.50 · Open Payments source 2025-08-28 · Axsome Therapeutics, Inc. · $1,100.00 · Open Payments source 2025-09-09 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-09-09 · Axsome Therapeutics, Inc. · $81.36 · Open Payments source 2025-09-09 · Axsome Therapeutics, Inc. · $275.00 · Open Payments source 2025-09-10 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-09-10 · Axsome Therapeutics, Inc. · $122.07 · Open Payments source 2025-09-10 · Axsome Therapeutics, Inc. · $340.00 · Open Payments source 2025-10-01 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-10-01 · Axsome Therapeutics, Inc. · $121.30 · Open Payments source 2025-10-01 · Axsome Therapeutics, Inc. · $320.00 · Open Payments source 2025-11-17 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-11-17 · Axsome Therapeutics, Inc. · $83.73 · Open Payments source 2025-12-04 · Axsome Therapeutics, Inc. · $9.89 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$37,347.53	37	2025
Source payment records 2025-03-18 · Teva Pharmaceuticals USA, Inc. · $38.69 · Open Payments source 2025-03-18 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-03-23 · Teva Pharmaceuticals USA, Inc. · $213.76 · Open Payments source 2025-04-21 · Teva Pharmaceuticals USA, Inc. · $27.75 · Open Payments source 2025-04-21 · Teva Pharmaceuticals USA, Inc. · $19.60 · Open Payments source 2025-04-21 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-04-24 · Teva Pharmaceuticals USA, Inc. · $4,200.00 · Open Payments source 2025-04-25 · Teva Pharmaceuticals USA, Inc. · $36.50 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $72.87 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $893.28 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $3,094.00 · Open Payments source 2025-05-23 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-05-23 · Teva Pharmaceuticals USA, Inc. · $270.00 · Open Payments source 2025-06-26 · Teva Pharmaceuticals USA, Inc. · $125.00 · Open Payments source 2025-06-26 · Teva Pharmaceuticals USA, Inc. · $3,570.00 · Open Payments source 2025-06-26 · Teva Pharmaceuticals USA, Inc. · $750.00 · Open Payments source 2025-07-14 · Teva Pharmaceuticals USA, Inc. · $20.92 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $124.74 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $250.00 · Open Payments source 2025-10-02 · Teva Pharmaceuticals USA, Inc. · $125.00 · Open Payments source 2025-10-02 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-10-02 · Teva Pharmaceuticals USA, Inc. · $342.00 · Open Payments source 2025-10-23 · Teva Pharmaceuticals USA, Inc. · $120.31 · Open Payments source 2025-10-23 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-10-23 · Teva Pharmaceuticals USA, Inc. · $155.00 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $123.04 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $36.74 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $180.00 · Open Payments source 2025-12-03 · Teva Pharmaceuticals USA, Inc. · $106.92 · Open Payments source 2025-12-03 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-12-03 · Teva Pharmaceuticals USA, Inc. · $157.32 · Open Payments source 2025-12-07 · Teva Pharmaceuticals USA, Inc. · $420.00 · Open Payments source 2025-12-09 · Teva Pharmaceuticals USA, Inc. · $124.09 · Open Payments source 2025-12-09 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-12-09 · Teva Pharmaceuticals USA, Inc. · $330.00 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$28,729.47	46	2025
Source payment records 2025-02-06 · ABBVIE INC. · $7.42 · Open Payments source 2025-02-28 · ABBVIE INC. · $9.65 · Open Payments source 2025-03-19 · ABBVIE INC. · $7.74 · Open Payments source 2025-03-24 · ABBVIE INC. · $26.55 · Open Payments source 2025-04-03 · ABBVIE INC. · $9.33 · Open Payments source 2025-04-11 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-04-22 · ABBVIE INC. · $21.42 · Open Payments source 2025-04-22 · ABBVIE INC. · $23.80 · Open Payments source 2025-05-02 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-05-02 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-05-05 · ABBVIE INC. · $10.19 · Open Payments source 2025-05-22 · ABBVIE INC. · $9.14 · Open Payments source 2025-06-03 · ABBVIE INC. · $4.72 · Open Payments source 2025-06-12 · ABBVIE INC. · $32.55 · Open Payments source 2025-06-12 · ABBVIE INC. · $21.00 · Open Payments source 2025-07-02 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-07-07 · ABBVIE INC. · $23.21 · Open Payments source 2025-07-21 · ABBVIE INC. · $8.25 · Open Payments source 2025-07-28 · ABBVIE INC. · $9.69 · Open Payments source 2025-08-04 · ABBVIE INC. · $4.00 · Open Payments source 2025-09-04 · ABBVIE INC. · $6.57 · Open Payments source 2025-09-15 · ABBVIE INC. · $6.46 · Open Payments source 2025-09-15 · ABBVIE INC. · $350.00 · Open Payments source 2025-09-15 · ABBVIE INC. · $124.63 · Open Payments source 2025-09-18 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-09-25 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-10-13 · ABBVIE INC. · $4.21 · Open Payments source 2025-10-14 · ABBVIE INC. · $13.80 · Open Payments source 2025-10-23 · ABBVIE INC. · $5.71 · Open Payments source 2025-10-28 · ABBVIE INC. · $10.13 · Open Payments source 2025-10-28 · ABBVIE INC. · $114.65 · Open Payments source 2025-10-28 · ABBVIE INC. · $1,017.50 · Open Payments source 2025-11-06 · ABBVIE INC. · $6.67 · Open Payments source 2025-11-10 · ABBVIE INC. · $19.63 · Open Payments source 2025-11-13 · ABBVIE INC. · $3,500.00 · Open Payments source 2025-11-20 · ABBVIE INC. · $24.61 · Open Payments source 2025-11-20 · ABBVIE INC. · $348.00 · Open Payments source 2025-11-20 · ABBVIE INC. · $22.34 · Open Payments source 2025-12-04 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-12-08 · ABBVIE INC. · $4.24 · Open Payments source 2025-12-10 · ABBVIE INC. · $270.00 · Open Payments source 2025-12-10 · ABBVIE INC. · $124.99 · Open Payments source 2025-12-11 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-12-15 · ABBVIE INC. · $11.90 · Open Payments source 2025-12-18 · ABBVIE INC. · $2,500.00 · Open Payments source 2025-12-22 · ABBVIE INC. · $14.77 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$25,837.95	41	2025
Source payment records 2025-02-20 · Alkermes, Inc. · $15.77 · Open Payments source 2025-03-03 · Alkermes, Inc. · $24.07 · Open Payments source 2025-03-06 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-03-12 · Alkermes, Inc. · $126.00 · Open Payments source 2025-03-18 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-03-20 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-04-02 · Alkermes, Inc. · $25.16 · Open Payments source 2025-04-04 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-04 · Alkermes, Inc. · $125.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $24.95 · Open Payments source 2025-04-05 · Alkermes, Inc. · $43.80 · Open Payments source 2025-04-05 · Alkermes, Inc. · $353.96 · Open Payments source 2025-04-05 · Alkermes, Inc. · $238.26 · Open Payments source 2025-04-05 · Alkermes, Inc. · $2.88 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-05 · Alkermes, Inc. · $60.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $48.66 · Open Payments source 2025-04-05 · Alkermes, Inc. · $75.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.00 · Open Payments source 2025-04-17 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-04-18 · Alkermes, Inc. · $180.00 · Open Payments source 2025-04-18 · Alkermes, Inc. · $23.80 · Open Payments source 2025-04-18 · Alkermes, Inc. · $21.00 · Open Payments source 2025-04-24 · Alkermes, Inc. · $124.74 · Open Payments source 2025-04-25 · Alkermes, Inc. · $5,430.00 · Open Payments source 2025-05-02 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-05-09 · Alkermes, Inc. · $135.07 · Open Payments source 2025-05-13 · Alkermes, Inc. · $100.00 · Open Payments source 2025-05-13 · Alkermes, Inc. · $100.00 · Open Payments source 2025-06-03 · Alkermes, Inc. · $19.48 · Open Payments source 2025-06-05 · Alkermes, Inc. · $108.68 · Open Payments source 2025-06-18 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-06-18 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-06-27 · Alkermes, Inc. · $25.90 · Open Payments source 2025-07-03 · Alkermes, Inc. · $174.12 · Open Payments source 2025-08-15 · Alkermes, Inc. · $800.00 · Open Payments source 2025-09-19 · Alkermes, Inc. · $37.86 · Open Payments source 2025-10-23 · Alkermes, Inc. · $23.17 · Open Payments source 2025-11-07 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-11-17 · Alkermes, Inc. · $8.72 · Open Payments source 2025-11-25 · Alkermes, Inc. · $92.36 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$140.23	6	2025
Source payment records 2025-05-22 · Otsuka America Pharmaceutical, Inc. · $23.18 · Open Payments source 2025-08-26 · Otsuka America Pharmaceutical, Inc. · $24.76 · Open Payments source 2025-09-08 · Lundbeck LLC · $21.39 · Open Payments source 2025-09-29 · Otsuka America Pharmaceutical, Inc. · $27.30 · Open Payments source 2025-10-23 · Lundbeck LLC · $15.38 · Open Payments source 2025-12-15 · Otsuka America Pharmaceutical, Inc. · $28.22 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$123.72	2	2025
Source payment records 2025-04-09 · Alkermes, Inc. · $115.00 · Open Payments source 2025-11-17 · Alkermes, Inc. · $8.72 · Open Payments source
ARISTADA INITIO Normalized: aristada initio	Drug	Alkermes, Inc.	$115.00	1	2025
Source payment records 2025-04-09 · Alkermes, Inc. · $115.00 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$88.95	4	2025
Source payment records 2025-07-24 · Vanda Pharmaceuticals Inc. · $20.49 · Open Payments source 2025-08-28 · Vanda Pharmaceuticals Inc. · $16.48 · Open Payments source 2025-09-04 · Vanda Pharmaceuticals Inc. · $24.39 · Open Payments source 2025-12-11 · Vanda Pharmaceuticals Inc. · $27.59 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$86.41	4	2025
Source payment records 2025-05-09 · Collegium Pharmaceutical, Inc. · $24.81 · Open Payments source 2025-09-18 · Collegium Pharmaceutical, Inc. · $22.82 · Open Payments source 2025-12-09 · Collegium Pharmaceutical, Inc. · $19.30 · Open Payments source 2025-12-23 · Collegium Pharmaceutical, Inc. · $19.48 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$79.61	4	2025
Source payment records 2025-05-12 · Supernus Pharmaceuticals, Inc. · $17.56 · Open Payments source 2025-06-05 · Supernus Pharmaceuticals, Inc. · $18.87 · Open Payments source 2025-07-21 · Supernus Pharmaceuticals, Inc. · $23.09 · Open Payments source 2025-11-13 · Supernus Pharmaceuticals, Inc. · $20.09 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$71.90	3	2025
Source payment records 2025-06-02 · Takeda Pharmaceuticals U.S.A., Inc. · $23.92 · Open Payments source 2025-07-17 · Takeda Pharmaceuticals U.S.A., Inc. · $21.14 · Open Payments source 2025-11-06 · Takeda Pharmaceuticals U.S.A., Inc. · $26.84 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$52.49	1	2025
Source payment records 2025-05-20 · Teva Pharmaceuticals USA, Inc. · $52.49 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$38.31	2	2025
Source payment records 2025-06-30 · Tris Pharma Inc · $22.47 · Open Payments source 2025-10-06 · Tris Pharma Inc · $15.84 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$30.59	1	2025
Source payment records 2025-12-01 · Neurocrine BioSciences, Inc. · $30.59 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$24.80	1	2025
Source payment records 2025-09-25 · Corium, LLC · $24.80 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$23.59	1	2025
Source payment records 2025-10-13 · Janssen Pharmaceuticals, Inc · $23.59 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$14.61	1	2025
Source payment records 2025-10-16 · Otsuka America Pharmaceutical, Inc. · $14.61 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$14.61	1	2025
Source payment records 2025-10-16 · Otsuka America Pharmaceutical, Inc. · $14.61 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
TRINTELLIX trintellix	2025	Trintellix	2024	22 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Duloxetine Hcl	Duloxetine Hcl	181	31
Clonazepam	Clonazepam	175	29
Trazodone Hcl	Trazodone Hcl	149	33
Quetiapine Fumarate	Quetiapine Fumarate	145	24
Buspirone Hcl	Buspirone Hcl	135	30
Lorazepam	Lorazepam	101	16
Lamotrigine	Lamotrigine	98	18
Aripiprazole	Aripiprazole	92	22
Bupropion Xl	Bupropion Hcl	91	21
Gabapentin	Gabapentin	89	25
Sertraline Hcl	Sertraline Hcl	87	20
Olanzapine	Olanzapine	72	13
Fluoxetine Hcl	Fluoxetine Hcl	62	16
Mirtazapine	Mirtazapine	62	suppressed
Alprazolam	Alprazolam	60	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	50	16
Venlafaxine Hcl Er	Venlafaxine Hcl	48	suppressed
Doxepin Hcl	Doxepin Hcl	46	15
Zolpidem Tartrate	Zolpidem Tartrate	46	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	39	suppressed
Lurasidone Hcl	Lurasidone Hcl	34	suppressed
Divalproex Sodium Er	Divalproex Sodium	32	suppressed
Diazepam	Diazepam	31	suppressed
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	28	12
Hydroxyzine Hcl	Hydroxyzine Hcl	27	suppressed
Topiramate	Topiramate	27	suppressed
Benztropine Mesylate	Benztropine Mesylate	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	23	suppressed
Lithium Carbonate Er	Lithium Carbonate	23	suppressed
Divalproex Sodium	Divalproex Sodium	22	suppressed
Trintellix	Vortioxetine Hydrobromide	22	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	21	suppressed
Vilazodone Hcl	Vilazodone Hcl	19	suppressed
Prazosin Hcl	Prazosin Hcl	17	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	14	suppressed
Lithium Carbonate	Lithium Carbonate	14	suppressed
Risperidone	Risperidone	14	suppressed
Clozapine	Clozapine	13	suppressed
Haloperidol	Haloperidol	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Quviviq	Daridorexant Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$306,739.77 · 379 records	E.R. Squibb & Sons, L.L.C.	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, REXULTI, TRINTELLIX, UZEDY, VRAYLAR	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Trintellix play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Takeda Pharmaceuticals U.S.A., Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error

What the public records show

General Payments

Research & Ownership